Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

RTTNews | 290 dni temu

Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) and gene editing company CRISPR Therapeutics, Inc. (CRSP) announced Monday that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).

RTTNews | 661 dni temu

Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the company has entered into a definitive agreement under which Vertex will acquire privately-held biotechnology company ViaCyte for $320 million in cash.

RTTNews | 920 dni temu

Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.

RTTNews | 926 dni temu

U.S. Retail Sales Rise Less Than Expected In December

The Commerce Department released a report on Thursday showing retail sales in the U.S. increased by less than expected in the month of December.

RTTNews | 5g 7 minut temu

U.S. Weekly Jobless Claims Rebound To 217,000

A report released by the Labor Department on Thursday showed first-time claims for U.S. unemployment benefits rebounded by more than expected in the week ended January 11th.

RTTNews | 5g 9 minut temu

UK Modest GDP Growth Disappoints

The UK economy grew only marginally in November underpinned by the services sector, after two consecutive contractions, official data showed, which has strengthened the scope for more monetary policy easing from the Bank of England as inflation also softened unexpectedly at the end of 2024. Gross domestic product edged up 0.1 percent on a monthly basis in November.

RTTNews | 5g 39 minut temu

Bay Street Likely To Open Higher

Canadian shares may open on a positive note on Thursday, tracking higher bullion prices and firm European stocks. The market is likely to edge higher also on hopes of some monetary easing by the Federal Reserve this year.

RTTNews | 5g 40 minut temu

EURUSD	1.02764	GBPUSD	1.21904	AUDUSD	0.62028
USDJPY	156.015	USDCAD	1.43846	USDCHF	0.91214